诊断路径优化后对不确定甲状腺结节细胞学行ThyroSPEC分子检测的前瞻性验证
本研究在集中式医疗系统中前瞻性纳入首批615例连续的不确定甲状腺结节(ITN)患者,在实施反射性分子检测后收集完整临床资料,验证一种本地开发的低成本分子检测的诊断准确性,并评估引入分子检测对人群层面的影响。结果显示该检测阴性预测值为76-91%[CI 66-95%],阳性预测值为46-65%[CI 37-75%];引入分子检测后诊断率提高14%(p=0.2442),重复细针穿刺减少24%(p=0.05)。结论认为分子检测改善术前风险分层,但中风险突变需进一步分层,结合临床因素(尤其超声恶性风险分层)可能提高恶性肿瘤检出敏感性。
要点
- 本地低成本分子检测用于ITN的NPV为76-91%,PPV为46-65%。
- ATA中 suspicion 超声类别敏感性最高(80%),高 suspicion 类别最低(46%)。
- 引入分子检测后重复FNA减少24%(p=0.05),诊断率提高14%(p=0.2442)。
核心结论
- 分子检测改善术前风险分层,但中风险突变需进一步分层。
- 结合临床因素(尤其超声恶性风险分层)与分子检测可能提高恶性肿瘤检出敏感性。
- 引入分子检测即使在低切除率环境下也带来一定临床获益,并直接影响手术决策。
- 本研究说明本地诊断路径对确保分子检测适当整合以获得最佳结局的重要性。
研究设计与样本
- 前瞻性收集集中式医疗系统中实施反射性分子检测后首批615例连续ITN患者的完整临床资料。
- 临床资料包括患者病史、结节发现方式、临床评估、超声恶性风险分层、细胞学、分子检测、手术或随访及外科医生手术决策记录。
- 计算分子检测准确性及引入分子检测的影响,并建立多变量回归模型识别对ITN最具诊断意义的临床因素。
主要发现
- 本地开发的低成本分子检测仅使用标准液基细胞学FNA残留材料,在ITN中NPV为76-91%[CI 66-95%],PPV为46-65%[CI 37-75%]。
- 敏感性在ATA中 suspicion 超声类别最高(80%[CI 63-92%]),在ATA高 suspicion 超声类别最低(46%[CI 19-75%])。
- 引入分子检测后诊断率提高14%(p=0.2442),重复FNA减少24%(p=0.05)。
- 在切除的突变阳性患者中,76%以突变为手术主要原因;高风险突变与手术等待时间缩短58%(p=0.0001)相关。
- 分子检测阴性患者中26%接受了手术;多变量回归显示分子检测和USMR与恶性肿瘤显著相关。
关键数值与推荐
- 分子检测NPV 76-91%[CI 66-95%],PPV 46-65%[CI 37-75%](ITN,仅用液基细胞学FNA残留材料)。
- 敏感性:ATA中 suspicion 类别80%[CI 63-92%],ATA高 suspicion 类别46%[CI 19-75%]。
- 引入分子检测后诊断率提高14%(p=0.2442),重复FNA减少24%(p=0.05)。
- 突变阳性切除患者中76%以突变为手术主要原因;高风险突变与手术等待缩短58%(p=0.0001)相关。
- 分子检测阴性患者中26%接受手术。
临床怎么用
- 分子检测可用于ITN的术前风险分层,但中风险突变需进一步分层(作者结论)。
- 作者认为结合临床因素(尤其USMR)与分子检测可能提高恶性肿瘤检出敏感性。
- 作者指出引入分子检测即使在低切除率环境下也带来一定临床获益并直接影响手术决策。
- 作者强调本地诊断路径对确保分子检测适当整合以获得最佳结局的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Molecular testing for cytologically indeterminate thyroid nodules (ITNs) is often reported with incomplete data on clinical assessment and ultrasound malignancy risk (USMR) stratification. This study aimed to clinically validate the diagnostic accuracy of a novel molecular test, assess the incremental preoperative malignancy risk of other clinical factors, and measure the impacts of introducing molecular testing at the population level. Methods: Comprehensive clinical data were collected prospectively for the first 615 consecutive patients with ITNs in a centralized health care system following implementation of a reflexive molecular test. Clinical data include patient history, method of nodule discovery, clinical assessment, USMR, cytology, molecular testing, and surgery or follow-up along with surgeon notes on surgical decision-making. Accuracy of molecular testing and the impact of the introduction of molecular testing were calculated. A multivariable regression model was developed to identify which clinical factors have the most diagnostic significance for ITNs. Results: A locally developed, low-cost molecular test achieved a negative predictive value (NPV) of 76-91% [confidence interval, CI 66-95%] and a positive predictive value (PPV) of 46-65% [CI 37-75%] in ITNs using only residual material from standard liquid cytology fine-needle aspiration (FNA). Sensitivity was highest (80%; [CI 63-92%]) in the American Thyroid Association (ATA) intermediate-suspicion ultrasound category, and lowest (46%; [CI 19-75%]) in the ATA high-suspicion ultrasound category. Following implementation of molecular testing, diagnostic yield increased by 14% (p = 0.2442) and repeat FNAs decreased by 24% (p = 0.05). Mutation was the primary reason for surgery in 76% of resected, mutation-positive patients. High-risk mutations were associated with a 58% (p = 0.0001) shorter wait for surgery. Twenty-six percent of patients with a negative molecular test result underwent surgery. Multivariable regression highlighted molecular testing and USMR as significantly associated with malignancy. Conclusions: Molecular testing improves preoperative risk stratification but requires further stratification for intermediate-risk mutations. Incorporation of clinical factors (especially USMR) with molecular testing may increase the sensitivity for detection of malignancy. Introduction of molecular testing offers some clinical benefits even in a low resection rate setting, and directly influences surgical decision-making. This study illustrates the importance of the local diagnostic pathway in ensuring appropriate integrated use of molecular testing for best outcomes.
引用
- Stewardson P, Eszlinger M, Wu J, et al. Prospective Validation of ThyroSPEC Molecular Testing of Indeterminate Thyroid Nodule Cytology Following Diagnostic Pathway Optimization. Thyroid. 2023. PMID: 37742115. doi:10.1089/thy.2023.0255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。